Expression and Diagnostic Evaluation of the Human Tumor–Associated Antigen RCAS1 in Pancreatic Cancer

Introduction Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is one of the membrane molecules expressed on human cancer cells and is presumed to play a protective role for tumor cells against immune surveillance by inhibition of clonal expansion and induction of cell death in immunocytes. Aims To address whether RCAS1 is expressed in pancreatic cancer and whether serologic diagnostic evaluation is useful compared with that of carbohydrate antigen 19–9 (CA19–9) and soluble Fas ligand. Methodology Immunohistochemical expression of RCAS1 was examined by staining with a 22–1-1 monoclonal antibody, and serum RCAS1 concentrations were determined by an enzyme-linked immunosorbent assay in 20 cases of ductal adenocarcinoma of the pancreas and other pancreatic diseases. Results Immunohistochemically, RCAS1 detection occurred in 100% (20/20) of ductal adenocarcinoma of the pancreas cases, 100% (6/6) of intraductal papillary–mucinous adenoma of the pancreas cases, and 40% (2/5) of chronic pancreatitis cases. RCAS1 was found in the cytoplasm of cancer cells and ductal cells. Serum RCAS1 concentrations in patients with ductal adenocarcinoma of the pancreas were significantly higher than those in patients with chronic pancreatitis (p < 0.0001), acute pancreatitis (p < 0.005), and autoimmune pancreatitis (p < 0.001). RCAS1 concentrations in patients with intraductal papillary–mucinous adenoma of the pancreas were also significantly higher than those in patients with chronic pancreatitis (p < 0.05) and autoimmune pancreatitis (p < 0.05). Positive serum RCAS1 samples (concentration, ≥10 U/mL) were found most often in cases of pancreatic neoplasm (80% [16/20], ductal adenocarcinoma of the pancreas; and 60% [3/5], intraductal papillary–mucinous adenoma of the pancreas). By contrast, in cases of pancreatic inflammatory diseases, raised concentrations occurred in 9.4% (3/32) of chronic pancreatitis cases, none (0/6) of acute pancreatitis cases, and none (0/8) of autoimmune pancreatitis cases. The sensitivity of CA19–9 for ductal adenocarcinoma of the pancreas was 75% and the specificity was 73.1% compared with chronic pancreatitis. On the other hand, the sensitivity of RCAS1 for ductal adenocarcinoma of the pancreas was 80% and the specificity was 96.2% compared with chronic pancreatitis. The specificity of RCAS1 for chronic pancreatitis was higher than that of CA19–9. Serum soluble Fas ligand concentrations were not considerably different among these patients. Conclusions RCAS1 was highly expressed in ductal adenocarcinoma of the pancreas, and serum RCAS1 concentrations in patients with ductal adenocarcinoma of the pancreas were significantly higher than those in patients with other inflammatory pancreatic diseases. Our results indicate that serum RCAS1 concentrations could be a new marker in screening procedures for pancreatic cancer.

[1]  K. Sugimachi,et al.  Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. , 2001, Cancer letters.

[2]  Hidetoshi Takahashi,et al.  RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin. , 2001, Journal of dermatological science.

[3]  J. Sahel,et al.  Intraductal papillary or mucinous tumors (IPMT) of the pancreas: Report of a case series and review of the literature , 2001, American Journal of Gastroenterology.

[4]  S. Hirohashi,et al.  Invasive carcinoma derived from intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic and immunohistochemical study of eight cases , 2001, Virchows Archiv.

[5]  H. Kitagawa,et al.  Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. , 2001, International journal of oncology.

[6]  H. Kuwano,et al.  Circulating soluble Fas ligand in patients with gastric carcinoma , 2000, Cancer.

[7]  M. Nakashima,et al.  Expression and prognostic significance in lung cancer of human tumor‐associated antigen RCAS1 , 2000, International journal of cancer.

[8]  T. Chiba,et al.  Clinical analysis of autoimmune-related pancreatitis , 2000, American Journal of Gastroenterology.

[9]  U. Rodeck,et al.  Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  M. Tempero,et al.  AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. , 1999, Gastroenterology.

[11]  Higashi,et al.  Autoimmune pancreatitis with F-18 fluoro-2-deoxy-D-glucose PET findings , 1999, Clinical nuclear medicine.

[12]  K. Okumura,et al.  The alteration of fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo? , 1999, Hepatology.

[13]  M. Nakashima,et al.  Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1 , 1999, Nature Medicine.

[14]  S. Shott,et al.  Immunoregulation in pancreatic cancer patients , 1999, Cancer Immunology, Immunotherapy.

[15]  T. Murayama,et al.  Levels of soluble FasL and FasL gene expression during the development of graft‐versus‐host disease in DLT‐treated patients , 1999, British journal of haematology.

[16]  K. Ohshima,et al.  Elevated serum soluble Fas ligand in natural killer cell proliferative disorders , 1998, British journal of haematology.

[17]  Y. Yazaki,et al.  Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease , 1998, Bone Marrow Transplantation.

[18]  T. Kaku,et al.  Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Duffy.  CA 19-9 as a Marker for Gastrointestinal Cancers: A Review , 1998, Annals of clinical biochemistry.

[20]  J. Devière,et al.  Intraductal papillary and mucinous tumors of the pancreas: accuracy of preoperative computed tomography, endoscopic retrograde pancreatography and endoscopic ultrasonography, and long-term outcome in a large surgical series. , 1998, Gastrointestinal endoscopy.

[21]  D. Gouma,et al.  Incidence and clinical findings of benign, inflammatory disease in patients resected for presumed pancreatic head cancer. , 1997, Gastrointestinal endoscopy.

[22]  James D. Evans,et al.  Chronic pancreatitis and pancreatic carcinoma. , 1997, Postgraduate medical journal.

[23]  K. Isselbacher,et al.  Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Green,et al.  Human lung carcinomas express Fas ligand. , 1997, Cancer research.

[25]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[26]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[27]  L. Owen-Schaub,et al.  Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. , 1996, Cancer research.

[28]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[29]  M. Makuuchi,et al.  Duct-ectatic type of mucin producing tumor of the pancreas--new concept of pancreatic neoplasia. , 1996, Hepato-gastroenterology.

[30]  T. Kaku,et al.  A novel tumor‐associated antigen expressed in human uterine and ovarian carcinomas , 1996, Cancer.

[31]  D. L. Sobin,et al.  Histological Typing of Tumours of the Exocrine Pancreas , 1996, World Health Organization International Histological Classification of Tumours.

[32]  K. Yoshino,et al.  Metalloproteinase-mediated Release of Human Fas Ligand , 1995 .

[33]  H. Nakano,et al.  Establishment of a new human uterine cervical adenocarcinoma cell-line, siso, and its reactivity to anticancer reagents. , 1995, International Journal of Oncology.

[34]  T. Colby,et al.  Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving? , 1995, Annals of surgery.

[35]  P. Pour,et al.  Atlas of Exocrine Pancreatic Tumors , 1994, Springer Japan.

[36]  J. Devière,et al.  Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. , 1991, Gastroenterology.

[37]  W. Steinberg.  The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.

[38]  D. Pleskow,et al.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.

[39]  A. Warshaw,et al.  What's New In General Surgery: Pancreatic Cancer in 1988 Possibilities and Probabilities , 1988, Annals of surgery.

[40]  M. Büchler,et al.  CA 19‐9 and pancreatic adenocarcinoma , 1986, Cancer.